Drug intelligence / Profile preview

SL017

Development stage: Discontinued
Lead developer: Quest PharmaTech
Modality: Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Topical

Overview

SL017 is a photosensitizer drug that was initially developed by Quest PharmaTech. It has been investigated for use in the treatment of acne, actinic keratosis, unspecified cancers/tumors, keratoses, and skin infections. The primary mechanism involves photodynamic therapy (PDT), where the drug targets hair follicle regenerative structures while sparing surrounding tissues. This approach has also been studied for cosmetic hair removal applications. The global highest R&D status for SL017 is discontinued.

Beyond the preview

Go deeper on SL017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SL017.

Explore the full profile